Fredric Gorin, M.D., Ph.D.
Professor and Chair
Lawrence J. Ellison Ambulatory Care Center
4860 Y St., Suite 0100
Sacramento, CA 95817
Clinical & Research Interests
Fredric Gorin lectures on the peripheral nervous system, particularly with respect to diagnosing neuropathies, treating neuropathic cellular mechanisms of drug actions, drug development, and brain cancers. He has authored more than 50 publications on neurology disorders and dysautonomiast. Dr. Gorin's patented drug agents at UCD that prevent or slow the recurrent of highly aggressive brain novel agents and advance a lead compound for clinical evaluation.
Washington University School of Medicine
St. Louis, Missouri
M.D., Ph.D. 1979 (medical scientist training program)
1979 (doctorate in computer-based drug design in Biophysics and Physiology)
Internship in Internal Medicine
Jewish Hospital of St. Louis
St. Louis, Missouri
Professional Memberships1985 Neurology, American Board of Psychiatry and Neurology- Boarded
1987 American Association for Advancement of Science
1987 American College of Physicians & Surgeons
1990 American Medical Association
1988 American Society for Neurological Investigation
1988 California Childrens' Services (Neurology)
1988-1993 Senior clinical neurologist for MDA Neuromuscular Clinics, U.C. Davis
1995-present Society for Experimental Biology and Medicine (member and editorial board)
1985-present Society for Neuroscience (regular member)
1996-present American Physiological Society (elected regular member)
1996-present The American Neurological Association (elected regular member)
1997-present The American Academy of Neurology (elected regular member)
2000-present The American Academy of Immunotherapy (member)
2004-present The Society for Neuro-Oncology
2003-present American Academy for Cancer Research
2009- American Chemical Society (elected regular member)
2009- America's Top Doctors 2010- American Society for Neurological Therapeutics (ASENT)
Defined drug pharmacophore for enkephalin neuropeptides bound to mu opioid receptor subclass using computer-based drug design
Cloned and chromosomally mapped the first human metabolic myopathy using forward genetics (McArdles Disease)
Demonstrated that neuromuscular regeneration of fast twitch glycolytic skeletal muscles has altered glycolytic gene expression causing the muscle to be susceptible to damage with high intensity exercise
Demonstrated that neurally coordinated metabolic gene expression in type 2 skeletal muscle fibers is mediated by calcium flux through the sarcoplasmic reticulum regulating transcript stability
Designed and co-developed concept-based vector space model with automated relevance feedback that could be employed to reconcile diverse neuroanatomical terms and acronyms. Categorized metadata used to retrieve semi-structured graphical neuroscientific information
Identified a novel drug mechanism of action by which a new class of anti-cancer small molecules kill proliferating and non-proliferating hypoxic brain and breast cancer initiating cells
Initiated Telestroke/TeleNeurology Programs at UC Davis Health System
U.S. Patent 6,096,520 (Aug 1,2000) "Brain Glycogen Phosphorylase Cancer Antigen " European Patent no /15.03.99/. 97930228.8-2106 (Ludwig Institute for Cancer Research, Brussels, ref: LUD 5445.1) and US patent 6,096,520, Vincent Brichard, Aline van Pel, Thierry Boon-Falleur, Fredric Gorin inventor/co-inventor
Record of Invention UC Case No. 98-229, (filed Mar, 18, 1998) “Novel Cancer Drug Target and Class of Chemotherapeutic Agent, Fredric Gorin, Peter Cala
US Patent # 7,863,415 (January 4, 2011) International Patent Application (WHO 2005/073247) “Amino acid and peptide conjugates of amiloride and methods of use thereof” F. Gorin, M. Nantz. "Novel Bioactive Amino Acid and Peptide Conjugates of Amiloride" (Fredric Gorin, Michael Nantz)
US Patent # 8,546,322 “Inhibitors of Intracellular Urokinase Plasminogen Activator and Methods of Use Thereof”. F. Gorin, M. Nantz.
Select Recent Publications
Andreozzi E, Wang P, Valenzuela A, Tu C, Gorin F, Dhenain M, Louie A. Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging. Bioconjug Chem. 2013 Sep 18;24(9):1455-67. doi: 10.1021/bc300605f. Epub 2013 Sep 4. PubMed PMID: 24004269.
Leon LJ, Pasupuleti N, Gorin F, Carraway KL 3rd. A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells. PLoS One. 2013 Apr 30;8(4):e63038. doi:10.1371/journal.pone.0063038. Print 2013. PubMed PMID: 23646172; PubMed Central PMCID: PMC3639988.
Pasupuleti N, Leon L, Carraway KL 3rd, Gorin F. 5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor. J Pharmacol Exp Ther. 2013 Mar;344(3):600-15. doi: 10.1124/jpet.112.200519. Epub 2012 Dec 14. PubMed PMID: 23241369; PubMed Central PMCID: PMC3583503.
Massey AP, Harley WR, Pasupuleti N, Gorin FA, Nantz MH. 2-Amidino analogs ofglycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2635-9. doi: 10.1016/j.bmcl.2011.12.123. Epub 2012 Jan 4. PubMed PMID: 22366654; PubMed Central PMCID: PMC3329872.
Sun Y, Hatami N, Yee M, Phipps J, Elson DS, Gorin F, Schrot RJ, Marcu L. Fluorescence lifetime imaging microscopy for brain tumor image-guided surgery. J Biomed Opt. 2010 Sep-Oct;15(5):056022. doi: 10.1117/1.3486612. PubMed PMID: 21054116; PubMed Central PMCID: PMC2966493.
Harley W, Floyd C, Dunn T, Zhang XD, Chen TY, Hegde M, Palandoken H, Nantz MH, Leon L, Carraway KL 3rd, Lyeth B, Gorin FA. Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas. Brain Res. 2010 Dec 2;1363:159-69. doi: 10.1016/j.brainres.2010.09.059. Epub 2010 Oct 13. PubMed PMID: 20869350; PubMed Central PMCID: PMC2996276.